

2-23-2021

Determinants of the Outcome of the Transition of Children with Sickle Cell Disease to Adult Programs.

Samir K. Ballas
Thomas Jefferson University

Gaye Riddick-Burden
Thomas Jefferson University

Elisabeth Congdon-Martin
Thomas Jefferson University

Follow this and additional works at: https://jdc.jefferson.edu/cardeza_foundation

 Part of the [Hematology Commons](#)

[Let us know how access to this document benefits you](#)

Recommended Citation

Ballas, Samir K.; Riddick-Burden, Gaye; and Congdon-Martin, Elisabeth, "Determinants of the Outcome of the Transition of Children with Sickle Cell Disease to Adult Programs." (2021). *Cardeza Foundation for Hematologic Research*. Paper 65.
https://jdc.jefferson.edu/cardeza_foundation/65

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Cardeza Foundation for Hematologic Research by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

Determinants of the outcome of the transition of children with sickle cell disease to adult programs

Samir K. Ballas¹, Gaye Riddick-Burden², Elisabeth Congdon-Martin³

¹Cardeza Foundation for Hematologic Research, Department of Medicine, Sidney Medical, Thomas Jefferson University, Philadelphia, PA

²Department of Medicine, Division of Internal Medicine, Thomas Jefferson University, Philadelphia, PA

³Department of Medicine, Division of Hematology Thomas Jefferson University, Philadelphia, PA

Corresponding author:

Samir K. Ballas, Cardeza Foundation for Hematologic Research, Department of Medicine, Sidney Kimmel Medical College, Thomas Jefferson University,
1020 Locust St, Suite390, Philadelphia, PA19107
Phone 856-745-6380
Fax 856 7950809
e-mail: samir.ballas@jefferson.edu

Number of words: 1,979

Number of pages: 11

Number of references: 29

Number of Tables: 0

Number of Figures: 2

The authors claim no conflict of interest

1

2 **Abstract**

3 Transition of adolescents with sickle cell disease (SCD) to adult programs is associated
4 with increased morbidity and mortality. The reasons for this poor outcome are not well known.
5 This report describes the various factors that affect the outcome of the transition process. These
6 include four inter-personal factors: country of residence, region within the country of residence,
7 the health care system and intra-personal factors. Each factor is described in some detail.
8 Understanding these factors and the establishment of guidelines or recommendations could
9 improve the outcome of this critical transition in the life of patients with SCD.

10

11 **Introduction**

12

13 Transitions are inevitable facts of life. Differences between an old and a new phase of life
14 could be a stark landscape that threatens the sense of security. We all experience many life
15 transitions. With time, most of us acclimatize to the new change and achieve a new sense of
16 stability and security. This sequence of events, however, does not occur when most children and
17 young adults with sickle cell disease (SCD) transition from pediatric to adult programs. Besides
18 the usual personal transitions, they face an additional serious transition of their medical care to
19 adult programs. Transition of medical care includes changes to the level, place or providers of
20 medical care as patients and families negotiate the complex health care system [1]. This process
21 is lengthy, tedious, expensive and its outcomes are often unpredictable, necessitating circuitous
22 trials. This transition is associated with increased morbidity and mortality as was described
23 previously [2]. There is a treacherous deep gap (Figure 1 Panel A [3]) between the pediatric and

1 adult programs and most children are not aware of it. The ultimate results of this transition are
2 dependent on several factors as shown in Figure 1 Panel B as well as personal experience and
3 publications by patients treated in different sickle cell centers across the United States [4-13].
4 This commentary reviews the determinants of the outcome of this transition.

5 The best method to determine the difficulties experienced by patients with SCD after
6 transition to adult care is to quote how the patients describe their own experience. To that end,
7 there are at least 9 books written by adult patients with SCD in which they describe the various
8 issues they encountered [4-12]. These will be referred to as needed in this commentary.

9

10

11 **1. Inter-personal conflicts**

12

13 *a. Conflicts with adult providers*

14 Medical care of children and adolescents with SCD is usually provided by pediatric
15 hematologists within a framework of state-of-the-art care including all aspects of the disease.
16 Physicians, nursing staff and ancillary personnel in the hospital and clinic demonstrate empathy
17 and provide comprehensive multi- disciplinary care.

18 The excellent care provided by pediatricians is eclipsed when the children are
19 transitioned to adult programs. Lack of empathy and mistrust complicate matters. Young adults
20 with SCD are surprised to have limited access to hematology specialists or other providers
21 specialized in caring for patients with SCD. Accordingly, they try to go back to their
22 pediatricians, seek care in any emergency department (ED), wander along a maze of maladaptive

1 behavior. As a result, some young adults continue to be seen in pediatric clinics and EDs until
2 they are in their late twenties or early thirties [14].

3 ***b. Conflicts with Emergency Departments' Personnel***

4 Emergency Departments (EDs) and their personnel are often the nemesis of patients,
5 especially adults, with SCD. One patient referred to the ED as “hell” and other patients referred
6 to it as “asylum” [4,6]. Emergency departments are the last resort patients go to after failing to
7 control their pain at home. The patients expect waiting for long periods before they are screened
8 and longer before receiving the desired treatment, if any [15]. Most painful is the body and
9 verbal language of some ED personnel including humiliating sneers and jeers [16].
10 Unfortunately, some patients may not seek care at all until they end up in an emergency room
11 with potentially life-threatening complications. In our experience, a few patients turned away
12 from the ED, were found dead at home the next day.

13 ***c. Conflicts with parents or guardians***

14

15 Rarely, some parents/guardians may declare that they are not responsible to take care of
16 their children once they are legally adults aged 18 years or more. In these cases, the young adults
17 have no choice but to pursue undesirable behaviors. More often, however, it is the young adults
18 who declare that they are adults now who can make their own decisions and not follow advice
19 from parents or guardians.

20 ***d. Conflicts with pediatric providers***

21

22 Although pediatricians provide excellent care for their patients with SCD, rarely, they
23 create a conflict in certain situations. Occasionally, a teenager less than 18 years old is
24 considered a problem patient because he/she has frequent painful crises (VOCs) that require

1 frequent and lengthy hospital admissions and the use of high doses of opioids. Such behavior is
2 considered typical of adults with SCD and, hence, justifies the transition of such patients to adult
3 programs. Most adult programs, however, refuse to accept these patients but a few do. The
4 germane issue in such situations is that the patient in question will be labeled a problem patient
5 that negatively affects his/her management as an adult for a long time.

6 Another situation pertains to pregnant girls. These are logically transitioned to obstetrics
7 and considered “adults” whose medical care should be provided by obstetricians, adult
8 hematologists or providers. Pediatricians consider a pregnant girl an adult and adult hematologist
9 consider her a child since she is less than 18 years old. There are no clear guidelines what to do
10 in such situations.

11 Another emerging barrier to the use of opioids in the management of sickle cell pain
12 pertains to the attitude of pediatric residents. Fearon et al [17] reported that certain negative
13 views of patients with SCD were prevalent among all pediatric residents. Moreover, less
14 experienced residents were less comfortable treating acute sickle cell pain and were more
15 concerned with addiction compared with more experienced residents.

16

17 **2. Country of Residence**

18

19 Population-based studies in the United States (US) showed a significantly higher rate of
20 deaths due to SCD in young adults compared to children or teenagers [18,19]. The transition
21 from pediatric to adult care is associated with loss of comprehensive care and seems to be the
22 major risk factor. Moreover, poor socio-economic conditions, different cultural and educational
23 factors probably also play a role in the outcome of transition. Recent study by Le et al [20] did

1 not confirm the dramatic increase in SCD-related mortality among young adults in Belgium as
2 was observed in the US [18,19]. The Belgian national healthcare system covers the medical costs
3 irrespective of patient age and employment. In addition, in Belgium there is a strong network of
4 hematologists that shares standard of care and patients have direct access to specialists and
5 secondary or tertiary hospitals [20]. Moreover, evictions, disparities, faulty accusations, rationing
6 of care, etc. are not major issues in Belgium the way they are in the US [8-10]. Noteworthy, the
7 outcome of transition in Belgium is impressive despite the fact that most patients with SCD in
8 Belgium are immigrant from central Africa a region known to have more severe forms clinical
9 SCD [20].

10

11 **3. Geography/Region within the country of residence**

12

13 Specific geographic issues within the country of residence should be considered in
14 analyzing the factors associated with increased morbidity and mortality after the transition of
15 adolescents and young adults with SCD to adult care. The Multicenter Study of Hydroxyurea
16 (MSH) in sickle cell anemia showed that management of VOCs at home, in acute care facilities,
17 and in the hospital, seems to be sex, age, and geographic region dependent [21]. Specifically, the
18 choice of the route of opioid administration was region dependent with the frequency of
19 utilization of oral opioids at home was significantly highest in the Northeast and lowest in the
20 West and the frequency of utilization of parenteral opioids in acute care facilities tended to be
21 highest in the West and lowest in the Midwest.

1 Anderson et al [22] reported that during 10 years of follow-up after transition from
2 pediatric to adult care, the rate of death in Atlanta was much lower than that in Philadelphia:
3 5.8% in Atlanta versus 22.2% in Philadelphia.

4 **4. Health care system**

5
6
7 The health care system in the US is the Achilles heel of the transition from pediatrics to
8 adult care programs. Its weakness is the major cause of disruption of the quality of care in the
9 adult setup [23]. The frequency of morbidity and mortality after transition to adult programs is
10 associated with the health insurance the patients have. Patients who had commercial coverage
11 had significantly less VOCs, hospital admissions and mortality than patients covered by
12 Medicaid [24]. Thus, the health care system is the major determinant of the outcome of transition
13 from pediatrics to adult care.

14 **5. Intra-personal Factors**

15
16
17 In post-adolescence, young adults with SCD feel free from adult interference. They
18 think they are now autonomous, having the right of self-determination. As a result, adherence to
19 medical care, follow-up, medication schedules, etc. gradually fade away. This happened in the
20 case of children who were on chronic blood exchange transfusion due to ischemic stroke. Once
21 they became adults aged 18 years, they refused to continue having exchange transfusion on a
22 regular basis as before despite all advice by their parents, pediatricians and adult hematologists.
23 These patients died within 3 -5 years after transition due to complications of their disease, mostly
24 recurrent severe stroke [25].

25

1 In Brazil, health coverage is not a major issue for patients with SCD. Patients who have
2 no private coverage are covered by the State. Patients are usually assigned to a Medical facility
3 close to their residence. Children followed in such Medical facilities continue to be followed in
4 the same facility when their care is transitioned from pediatrics to adult programs, after the age
5 of 18 years. In spite of this, morbidity and mortality increased significantly after transition as
6 shown in Figure 2 [26]. Lack of regular follow ups, compliance to treatment, family support and
7 lifestyle were the important factors contributing to the increased morbidity and mortality as
8 described at a single institution in Rio de Janeiro [26].

9

10 **Conclusion**

11 Understanding the determinants of transition outcome allows the establishments or the
12 revision of guidelines and recommendations for the transition process. Most important among
13 these is that no child below the age of 18 years should be transitioned to adult care due to
14 frequent VOCs that require relatively high doses of opioids. Similarly, pregnant girls should be
15 transferred to Obstetrics care during the pregnancy/post-partum time and back to pediatrics after
16 that. The American Academy of Pediatrics reviewed current trends and issues related to
17 adolescent pregnancy including the legal and policy implications of concern to pediatricians
18 [27]. On the other hand, transition to adult programs should not be delayed beyond the age of 25
19 years in the US in order to maintain coverage by the parents' health care status.

20

21 Once pediatricians realize that transition to adult programs should usually be between the
22 ages of 18 -25 years, the transition of each specific patient becomes individualized. Howard et al
23 [28] established a transition clinic for that purpose. St. Jude Hospital in Memphis MO also has

1 transition clinic for patients with SCD. In such a clinic the situation of each patient will be
 2 analyzed within the framework of his/her psychosocial status, family structure, education,
 3 severity of SCD and potential for employment. The clinic will include a pediatrician, adult
 4 provider specialized in SCD or a hematologist, nurse practitioner and a social worker. Health
 5 care coverage is often a problem in patients covered by Medicare or Medicaid. Benefits applied
 6 to patients with SCD vary among states. It is best if the billing department of the Institution in
 7 question helps finding the approved coverage for each patient according to the Affordable Health
 8 Care Act and beyond if applicable. The rules are complex and are described by the Centers of
 9 Medicare & Medicaid Services [29].

10

11 **Legends to Figures:**

12 Figure 1: (A) The treacherous gap in challenging transitions. Adapted from Science
 13 2019;363:24-26 with permission. (B) Determinants of the outcome of transition of
 14 children with sickle cell disease to adult programs.

15
 16 Figure 2: The mortality rate in under 5-year-old patients was lower than the mortality rate
 17 in the 6–11 age group. However, there was a significant difference in the
 18 mortality rates between the 6–11 and 12–18 age groups. After the age of 18 years,
 19 there was a significant and sudden increase in the mortality in the 19–29 age
 20 group. The mortality continued to increase significantly after the age of 30 years.
 21 From Rev Bras Hematol Hemoter 2018; 40(1): 37-42 with permission.

22


23 **References:**

- 24 1. Kim CS, Flanders SA. In the Clinic. Transitions of care. Ann Intern Med. 2013 Mar
 25 5;158(5 Pt 1):Itc3-1.
 26 2. Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999-
 27 2009). Pediatr Blood Cancer. 2013 Sep;60(9):1482-6.
 28 3. Wasalathanthri ND, Zaidi SS, Mahrt E, et al. Challenging transitions. Science. 2019 Jan
 29 4;363(6422):24-26.


- 1 4. Brandon WE. *Disabled My Life, The First Fifty Years With Sickle Cell Disease*.
2 Philadelphia, PA: Vacs Book Publishers; 1997.
- 3 5. Friend D. *Sickle: A Personal Story of Pain, Purpose, and Perseverance*. York, PA 2008.
- 4 6. Johnson JG, Williams Jr L. *Living With Sickle Cell Disease: The Struggle to Survive*.
5 Raleigh: Lulu Publishing; 2012.
- 6 7. Reed-Givhan J. *Now you see me, now you don't*. Charleston, SC: BookSurge; 2006.
- 7 8. Renee S. *The Stranger Within Me*. Thorofare NJ: Xlibris Corporation; 2010.
- 8 9. Tamedu O. *Menace In My Blood*. Lexington, KY: Trafford Publishing; 2005.
- 9 10. Tapper M. *In The Blood: Sickle Cell Anemia And The Politics Of Race*. Philadelphia:
10 University of Pennsylvania Press; 1999.
- 11 11. Wailoo K. *Dying in the city of the blues*. Chapel Hill: The University of North Carolina
12 Press; 2001.
- 13 12. Watkins T. *A Sick Life*. Emmaus, PA: Rodale; 2017.
- 14 13. Ballas S. K. *Issues Pertinent to Sickle Cell Pain*. *Sickle Cell Pain, Second Edition*.
15 Washington DC: International Association for the Study of Pain; 2014. p. 541-569.
- 16 14. Doulton DM. From cradle to commencement: transitioning pediatric sickle cell disease
17 patients to adult providers. *J Pediatr Oncol Nurs*. 2010 20100223 DCOM-
18 20100607;27(1532-8457 (Electronic)):119–123.
- 19 15. Smith SK, Johnston J, Rutherford C, et al. Identifying Social-Behavioral Health Needs of
20 Adults with Sickle Cell Disease in the Emergency Department. *J Emerg Nurs*. 2017
21 Sep;43(5):444-450.
- 22 16. Pentin PL. Drug seeking or pain crisis? Responsible prescribing of opioids in the
23 emergency department. *Virtual Mentor*. 2013 May;15(5):410-5.
- 24 17. Fearon A, Marsh A, Kim J, et al. Pediatric residents' perceived barriers to opioid use in
25 sickle cell disease pain management. *Pediatr Blood Cancer*. 2019 Feb;66(2):e27535.
- 26 18. Yanni E, Grosse SD, Yang Q, et al. Trends in pediatric sickle cell disease-related
27 mortality in the United States, 1983-2002. *J Pediatr*. 2009 Apr;154(4):541-5.
- 28 19. Lanzkron S, Carroll CP, Haywood C, Jr. Mortality rates and age at death from sickle cell
29 disease: U.S., 1979-2005. *Public Health Rep*. 2013 Mar-Apr;128(2):110-6.
- 30 20. Le PQ, Ferster A, Dedeken L, et al. Neonatal screening improves sickle cell disease
31 clinical outcome in Belgium. *J Med Screen*. 2018 Jun;25(2):57-63.
- 32 21. Ballas SK, Bauserman RL, McCarthy WF, et al. Utilization of analgesics in the
33 multicenter study of hydroxyurea in sickle cell anemia: effect of sex, age, and
34 geographical location [Comparative Study
35 Letter]. *Am J Hematol*. 2010 Aug;85(8):613–6.
- 36 22. Anderson N, Eckman JR, Ballas SK. Beyond the transition of adolescents and young
37 adults with sickle cell disease to adult care: Role of geography. *Am J Hematol*. 2017
38 Jun;92(6):E110-e112.
- 39 23. Minniti CP, Vichinsky E. Lifespan care in SCD: Whom to transition, the patients or the
40 health care system? *Am J Hematol*. 2017 Jun;92(6):487-489.
- 41 24. Ballas SK, Kanter J, Agodoa I, et al. Opioid utilization patterns in United States
42 individuals with sickle cell disease. *Am J Hematol*. 2018 Oct;93(10):E345-e347.
- 43 25. McLaughlin JF, Ballas SK. High mortality among children with sickle cell anemia and
44 overt stroke who discontinue blood transfusion after transition to an adult program.
45 *Transfusion*. 2016 May;56(5):1014-21.

- 1 26. Lobo CLC, Nascimento EMD, Jesus LJC, et al. Mortality in children, adolescents and
2 adults with sickle cell anemia in Rio de Janeiro, Brazil. Rev Bras Hematol Hemoter. 2018
3 Jan - Mar;40(1):37-42.
- 4 27. Committee on Adolescence. Addendum--adolescent pregnancy: current trends and issues.
5 Pediatrics. 2014 May;133(5):954-7.
- 6 28. Howard J, Woodhead T, Musumadi L, et al. Moving young people with sickle cell
7 disease from paediatric to adult services. Br J Hosp Med (Lond). 2010 Jun;71(6):310-4.
- 8 29. Centers for Medicare & Medicaid Services. CMS Office of Minority Health 2020.
9 Available from: <https://www.cms.gov/About-CMS/Agency-Information/OMH/index>
10 Accessed on March 24, 2020

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46



1
2
3
4



5